Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TSC1 involvement in bladder cancer: diverse effects and therapeutic implications

7 Feb 2013

Abstract excerpt

TSC1 is often mutated in bladder cancer. However the importance of this event in disease pathogenesis and its implications for therapy are uncertain. We used genomic sequencing to examine the involvement of TSC1 in bladder cancer, and signalling pathway analysis and small-molecule screening to identify targeted therapeutic strategies in TSC1 mutant bladder cancer cell lines. TSC1 loss of heterozygosity was seen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Genomics, phytochemicals, and oxidative stress
Share to Glutathione Transferases and Polymorphisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23401075
DOI: 10.1002/path.4176

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TSC1 involvement in bladder cancer: diverse effects and therapeutic implicationsPMID 23401075Read ↗

Emerging therapeutic targets in bladder cancer.Semantic proximity Read ↗

Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanismsSemantic proximity Read ↗

Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy.Semantic proximity Read ↗

AST-487 Inhibits RET Kinase Driven TERT Expression in Bladder Cancer.Semantic proximity Read ↗

AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17KSemantic proximity Read ↗

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.Semantic proximity Read ↗

Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors.Semantic proximity Read ↗

Genome Sequencing Identifies a Basis for Everolimus SensitivitySemantic proximity Read ↗

Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus.Semantic proximity Read ↗

TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implicationSemantic proximity Read ↗

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.Semantic proximity Read ↗

PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.